Table 2.

Annualized bleeding rate before and during BAY 81‐8973 treatment in Chinese and non‐Chinese patients treated on#x2010;demand or with prophylaxis

	On‐demand	Prophylaxis (Combined)a	P valueb
	Median (Q1; Q3)	Median (Q1; Q3)
Chinese patients	n = 6	n = 17
All bleedsc
Prestudy	69.5 (60.0; 76.0)	50.0 (24.0; 76.0)	0.289
First 6 mo	65.9 (59.6; 100.0)	2.0 (1.9; 4.2)	0.002*
Last 6 mo	61.3 (44.5; 89.1)	2.0 (0; 3.8)	0.002*
Joint bleeds
Prestudy	50.0 (28.0; 50.0)	40.0 (11.0; 50.0)	0.534
First 6 mo	42.1 (37.7; 58.6)	1.9 (0; 4.0)	0.002*
Last 6 mo	46.5 (32.4; 61.4)	0 (0; 2.1)	0.001*
Non‐Chinese patients	n = 15	n = 42
All bleedsc
Prestudy	27.0 (23.0; 58.0)	36.0 (18.0; 51.0)	0.992
First 6 mo	51.6 (36.1; 72.7)	3.8 (0.0; 7.9)	<0.0001*
Last 6 mo	58.5 (37.5; 77.0)	1.0 (0; 8.0)	<0.0001*
Joint bleeds
Prestudy	22.0 (15.0; 39.0)	24.0 (13.0; 45.0)	0.985
First 6 mo	36.9 (20.4; 58.5)	2.0 (0; 6.1)	<0.0001*
Last 6 mo	40.2 (22.5; 67.8)	1.0 (0; 6.2)	<0.0001*

Q1 = quartile 1; Q3 = quartile 3.

Prestudy refers to the 12‐mo period before LEOPOLD II.

^aCombined prophylaxis includes all patients who received BAY 81‐8973 prophylaxis in LEOPOLD II.

^bCombined prophylaxis vs on‐demand.

^cAll bleeds included spontaneous, trauma‐related and untreated bleeds as well as bleeds with missing reason.

^* P values < 0.05 were considered significant.